Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: oxycodone

Opioids Commonly Prescribed for Gout Attacks

Reuters Staff  |  July 9, 2019

NEW YORK (Reuters Health)—Nearly three in 10 patients seeking care at the emergency department (ED) for acute gout will be discharged with a prescription for opioids, new research shows. “Our study suggests a high use of prescription opioid in patients discharged from the ED with a diagnosis of gout, a condition that can be managed…

Filed under:ConditionsGout and Crystalline ArthritisResearch Rheum Tagged with:Arthritis Care & ResearchEmergency DepartmentGoutopioidPainPain Management

The Benefits of Blood Money: OxyContin & Ethics

Philip Seo, MD, MHS  |  March 18, 2019

On Feb. 9, 2019, protesters gathered at the Guggenheim Museum in New York City to lead a march down Fifth Avenue to the Metropolitan Museum of Art.1 As a general rule, news from the world of art is not a topic discussed in these pages, but if you indulge me for just a little bit…

Filed under:EthicsOpinionRheuminationsSpeak Out Rheum Tagged with:Arthur M. Sackler FoundationDr. Mortimer and Theresa Sackler Foundationopioid crisisopioid use disordersOxyContinPurdue PharmaRaymond and Beverly Sackler Foundation

The FDA Denies Approval for Remoxy Extended Release; Plus Knee OA Pain Treatment Moves into Phase 3 Trials

Michele B. Kaufman, PharmD, BCGP  |  September 6, 2018

The FDA has not approved extended release Remoxy, a gel capsule formulation of oxycodone, concluding that its potential benefits do not outweigh its risks…

Filed under:AnalgesicsDrug Updates Tagged with:CNTX-4975Knee Osteoarthritis (OA)knee painPainPain MedicationRemoxy ER

Opioids No Better Than NSAIDs for Chronic Back or Arthritis Pain

Lisa Rapaport  |  March 7, 2018

(Reuters Health)—Acetaminophen, ibuprofen and other nonsteroidal anti-inflammatory drugs (NSAIDs) are better than opioids at easing the intensity of chronic pain in the back, knees or hips, a U.S. experiment suggests. And opioids are no better than these other drugs at reducing how much pain interferes with daily activities, such as walking, working, sleeping or enjoying…

Filed under:AnalgesicsConditionsDrug UpdatesPain Syndromes Tagged with:Chronic painhiphip painKnee Osteoarthritis (OA)Nonsteroidal anti-inflammatory drugs (NSAIDs)NSAIDsOpioidsosteoarthritis (OA)PainPain Management

Case Review: Lupus Patient with Acute Disseminating Encephalomyelitis

Teresa Sosenko, MD, Anca Musetescu, MD, PhD, Neha Gandhi, MD, Scott Friedstrom, MD, & Diana Girnita, MD, PhD  |  January 19, 2018

Systemic lupus erythematosus (SLE) is an autoimmune-mediated rheumatic disease characterized by multisystem involvement that can cause significant morbidity and mortality. Acute disseminated encephalomyelitis (ADEM) is a rare, fulminant, autoimmune-mediated, demyelinating disease involving the white matter of the central nervous system (CNS), and is considered a manifestation of neuropsychiatric lupus. Few reported cases involve SLE and…

Filed under:ConditionsMeeting ReportsSystemic Lupus Erythematosus Tagged with:ACR/ARHP Annual MeetingbrainClinicalDiagnosisdruglab testLupusmagnetic resonance imagingMRIoutcomepatient careprednisonepsychological disorderrheumatologistrheumatologySystemic lupus erythematosusTreatmentX-ray

Neurontin Prescriptions Surge Amid Opioid Crisis

Cindy Devone-Pacheco  |  January 4, 2018

(Reuters Health)—Prescriptions for nerve pain medicines like Neurontin and Lyrica have more than tripled in recent years, driven by increased use among chronically ill older adults and patients already taking opioids, a U.S. study suggests. The proportion of U.S. adults prescribed Neurontin and other drugs in the same family of medicines climbed from 1.2% in…

Filed under:Drug Updates Tagged with:gabapentinoidsLyricanational opioid addiction epidemicNeurontinNeurontin prescription surgeopioid crisis

U.S. Life Expectancy Fell in 2016 as Opioid Overdoses Surged—CDC

Reuters Staff  |  December 26, 2017

NEW YORK (Reuters)—Life expectancy in the United States dipped in 2016 as the number of deaths due to opioid drug overdoses surged and total drug overdose deaths rose 21% to 63,600, the U.S. Centers for Disease Control and Prevention said on Thursday. Life expectancy fell to 78.6 years, a decrease of 0.1 year from 2015,…

Filed under:Uncategorized Tagged with:opioid crisisopioid drug overdosesU.S. Centers for Disease Control and PreventionU.S. opioid addiction epidemicUnited States life expectancy 2016

Unwise Choices: EHRs, PBMs, Drug Costs Are Leading to Physician Burnout

Simon M. Helfgott, MD  |  November 5, 2017

My dear electronic health records How do I dislike thee? Let me count the ways Adaptation of Sonnet 43 By Elizabeth Barrett Browning, 1806–1861 As my tenure as physician editor winds down, it’s worth reviewing some of the more nettlesome issues confronting clinicians that have been previously discussed in these pages and gauge their current…

Filed under:EMRsInsuranceOpinionPractice SupportRheuminationsSpeak Out RheumWorkforce Tagged with:burnoutCareercostsdrugEHRElectronic health recordsHealthcareinsurancepharmacy benefit managersphysicianPractice Managementrheumatologist

Cigna to End OxyContin Painkiller Coverage, Signs Contract for Alternative

Deena Beasley  |  October 5, 2017

(Reuters)—Amid a growing U.S. opioid addiction, health insurer Cigna Corp will stop covering OxyContin, the opioid painkiller sold by Purdue Pharma LP, as of January 1 and will instead cover an equivalent with a formulation less vulnerable to abuse, the company said on Wednesday. The insurer has signed a “value-based contract” with Collegium Pharmaceutical Inc…

Filed under:Drug Updates Tagged with:Cigna Corp.Collegium Pharmaceutical Incopioid crisisOxyContinpainkiller coveragePurdue Pharma LPU.S. opioid addictionXtampza ER

DEA Proposes Cutting Production of Come Opioids

Reuters Staff  |  August 7, 2017

(Reuters)—The U.S. Drug Enforcement Administration (DEA) on Friday proposed a 20% reduction in the manufacture of certain commonly prescribed opioid painkillers, as well as other controlled substances for next year. The proposal comes as U.S. regulators and lawmakers take steps to limit the supply of opioids—a class of drugs that include prescription painkillers and heroin—to…

Filed under:AnalgesicsDrug Updates Tagged with:Opioid abuseopioid crisisOpioids

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 6
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences